Not yet recruiting
April 22, 2019
March 18, 2020
The main purpose of this study is to investigate the feasibility of a follow-up larger RCT on the efficacy of Botanical Tincture to relieve abdominal pain in people with Irritable Bowel Syndrome Constipation Predominant (IBS-C).
The randomized pilot trial will address subject recruitment, retention, and subject compliance with protocol. A secondary is to learn if people with IBS-C are able to tolerate Botanical Tincture and the effect of taking Botanical Tincture on abdominal pain, bloating, and bowel movements.
|Experimental: Botanical Tincture
The 12-week study includes a 2-week screening, 8-week treatment, and 2-week withdrawal periods. A 2-week screening period will be used to establish the presence and persistence of trial entry criteria and train patients in the mode of data collection. Participants randomly assigned to the Botanical Tincture arm at Week 2 will take 2.5 ml by mouth once a day at any time during the day that they choose. Participants who received Botanical Tincture during the study will be followed by a 2-week randomized withdrawal design to address the need for maintenance treatment to prevent sign or symptom recurrence. The participant will be randomly reassigned to receive either Botanical Tincture or placebo at a dosage of 2.5 ml once a day by mouth at any time during the day that they prefer.
Drug: Botanical Tincture
Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. Participants randomized to Botanical Tincture will have a 2-week withdrawal period. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
|Placebo Comparator: Placebo
Participants randomly assigned to placebo arm at Week 2 will take 2.5 ml by mouth once a day at any time during the day that they choose during the 8-week treatment period.
Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
- Patients meeting ROME IV criteria for the diagnosis of irritable bowel syndrome that
requires that patients have had recurrent abdominal pain on average at least 1 day per
week during the previous 3 months that is associated with 2 or more of the following :
- Related to defecation (may be increased or unchanged by defecation)
- Associated with a change in stool frequency
- Associated with a change in stool form or appearance
- Abdominal Pain Intensity: average of worst daily (in past 24 hours) abdominal pain
score of >= 3 on a 0 to 10 point scale over last week
- Stool Frequency: or = 2 on 5-point scale [0 (absent) - 4 (very severe)] in
- English speakers, as all surveys are in English
- Patients with known hypersensitivity to any component of the trial drugs
- History of eating disorders
- Patients with a history of diseases with abdominal symptoms that can resemble IBS
- Presence of any other known acute or chronic gastrointestinal disorder
- History of abdominal surgery (cholecystectomy and appendectomy can be tolerated when
performed at least one year previously)
- Pregnancy or breast feeding
- Current or past history of alcohol dependence
- Based on lack of adequate scientific evidence to predict drug-drug interaction in
vivo, current use of strong inhibitors or inducers for CYP enzymes and participants
are instructed not to take any medications that are strong inhibitors or inducers for
CYP enzymes during the course of the study
- Vulnerable Subjects. The study will not include vulnerable subjects (such as, those
with limited autonomy or those in subordinate hierarchical positions). Children,
pregnant women, nursing home residents or other institutionalized persons, students,
employees, fetuses, prisoners, and persons with decisional incapacity will not be
Contact: Marc Brodsky, MD 203-276-4777 firstname.lastname@example.org
Contact: Suzanne Rose, PhD 203-276-7866 email@example.com
United States, Connecticut
Principal Investigator: Marc Brodsky, MD Stamford Hospital